Cancer · Austria
Acute myeloid leukaemia
How is it diagnosed today? Your family doctor usually arranges an urgent blood test, and may send you to a hospital specialist or straight to hospital. NHS
What do you need help with?
- Join a trialStudies open to new patients in your country, and abroad if you want.13 open trials in Austria
- Offer tissue or dataGive a sample or your health data to research.
- Get supportPatient groups, money and work, help for family.
- Access and costGetting a treatment that is not on offer here, and who pays.
- Questions for your doctorReady lists to print or copy before your next visit.
- Don't pay for thisOffers with no proof in people, and what to check first.
Where treatment stands
Four steps, from proven to unproven.
Approved in Austria
Usual treatment: Intensive chemo, sometimes a stem cell transplant. NHS
15 medicines are approved for this disease in Austria:
Show all 15
- Arsenic trioxide (Trisenox, Arsenic trioxide Accord, Arsenic trioxide medac) – approved in 2002
- Azacitidine (Onureg, Azacitidine Mylan, Azacitidine Kabi) – approved in 2008
- Cedazuridine and decitabine (Inaqovi, Inqovi) – approved in 2023
- Daunorubicin and cytarabine (Vyxeos liposomal, Vyxeos) – approved in 2018
- Decitabine (Dacogen, Decitabin Sandoz) – approved in 2012
- Gemtuzumab ozogamicin (Mylotarg) – approved in 2018
- Gilteritinib (Xospata) – approved in 2019
- Glasdegib (Daurismo) – approved in 2020
- Histamine dihydrochloride (Ceplene) – approved in 2008
- Ivosidenib (Tibsovo) – approved in 2023
- Melphalan (Phelinun) – approved in 2020
- Midostaurin (Rydapt) – approved in 2017
- Quizartinib (Vanflyta) – approved in 2023
- Venetoclax (Venclyxto, Venclexta) – approved in 2016
- Posaconazole (Noxafil, Posaconazole Accord, Posaconazole AHCL) – approved in 2005
An EU approval is valid in Austria. We did not check the national approvals in Austria, so some medicines under “Approved elsewhere” may be approved here too. We did not check whether they are sold or paid for there. Checked in the regulators' own texts on 11 Nov 2026.
Approved elsewhere (17)
- Cyclophosphamide (Frindovyx) – approved for it in the US
- Cytarabine (Cytarabine, Aracytine, Cytarabine Sandoz) – approved for it in the US and France
- Daunorubicin (Daunorubicin Hydrochloride, Daunoblastin, Cerubidine) – approved for it in the US, Switzerland, and France
- Doxorubicin (Doxorubicin Hydrochloride) – approved for it in the US
- Enasidenib (Idhifa) – approved for it in the US
- Etoposide (Celltop, Etopophos) – approved for it in France
- Filgrastim (Neupogen) – approved for it in the US
- Idarubicin (Zavedos, Idamycin PFS, Idarubicine Accord) – approved for it in the US and France
- Mercaptopurine (Purinethol) – approved for it in France
- Mitoxantrone (mitoXANTRONE) – approved for it in the US
- Olutasidenib (Rezlidhia) – approved for it in the US
- Revumenib (Revuforj) – approved for it in the US
- Sargramostim (Leukine) – approved for it in the US
- Thioguanine (Tabloid, Lanvis) – approved for it in the US and France
- Treosulfan (Grafapex) – approved for it in the US
- Tretinoin (Tretinoin, Vesanoid) – approved for it in the US, Switzerland, and France
- Ziftomenib (Komzifti) – approved for it in the US
Being tested in people
13 open trials in Austria, 635 worldwide. See the trials
- 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). (Phase 3)
- AG-120 (Phase 3)
- AG-221 (Phase 3)
- all-trans retinoic acid (ATRA) (Phase 3)
Only in the lab or in animals
Of the 20 newest articles, 2 were in animals and 1 in the lab. See them
No proof it works
Animal worm medicines (ivermectin, fenbendazole) for cancer: not approved, and not enough research in people to know if they help. American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025)
Join a trial
Studies that are taking new patients in Austria. The trial team decides who can join. Change the country at the top.
Phase 1: first tests in people · Phase 2: does it help? · Phase 3: compared with the usual treatment
1 open trial in Austria with these filters
Adding venetoclax to standard treatment for IDH1-mutated acute myeloid leukemia
NCT07075016 · ClinicalTrials.gov
- Feldkirch – AT-Feldkirch-IKHF
- Salzburg – AT-Salzburg-SALK
- Vienna – AT-Vienna-HANUSCH
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial team
Available abroad (25 trials)
Nearest region first. Travel and treatment abroad are often not paid for; ask your health insurer first.
Tests ivosidenib added to oral azacitidine in older leukemia patients
2025-521322-14-00 · EU Clinical Trials Register
Countries: France
- Bayonne, France – Centre Hospitalier de la Cote Basque
- Clamart, France – Hopital D Instruction Des Armées Percy
- Lille, France – Hopital Claude Huriez - CHU de Lille
Age 18 and over
Contact the trial teamTests ivosidenib after stem cell transplant in IDH1-mutated leukemia
NCT06717958 · ClinicalTrials.gov
Countries: Germany
- Aachen, Germany – Universitaetsklinikum Aachen AöR
- Chemnitz, Germany – Klinikum Chemnitz gGmbH
- Dresden, Germany – Technische Universitaet Dresden
Ages 18 to 75
Contact the trial teamTests AG-120 pill in advanced blood cancers with an IDH1 gene change
NCT02074839 · ClinicalTrials.gov
Countries: France, United States
- Marseille, France – Hôpital la Timone
- Pessac, France – Hopital Haut-Leveque
- Pierre-Bénite, France – Central Lyon Sud
Age 18 and over
Contact the trial teamTests ivosidenib with oral azacitidine in older adults with IDH1-mutated leukemia
NCT07463768 · ClinicalTrials.gov
Countries: France
- Angers, France – CHU Angers
- Bayonne, France – CH Côte Basque
- Besançon, France – CHU Besançon
Age 55 and over
Contact the trial teamReviews Ivosidenib use in France for adults with IDH1-mutated acute myeloid leukemia
NCT06377579 · ClinicalTrials.gov
Countries: France
- Amiens, France – Amiens - CHU
- Angers, France – Angers - CHU
- Bayonne, France – Bayonne - CH
Age 18 and over
Contact the trial teamTesting Enasidenib with Venetoclax and ASTX727 in Newly Diagnosed Acute Myeloid Leukemia
NCT06672146 · ClinicalTrials.gov
Countries: Puerto Rico, United States
- San Juan, Puerto Rico – San Juan City Hospital
- San Juan, Puerto Rico – Centro Comprensivo de Cancer de UPR
- Albuquerque, United States – University of New Mexico Cancer Center
Age 18 and over
Contact the trial teamTests olutasidenib with azacitidine in adults with IDH1-mutated acute myeloid leukemia
NCT07304011 · ClinicalTrials.gov
Countries: United States
- Los Angeles, United States – UCLA / Jonsson Comprehensive Cancer Center
- Orange, United States – UCI Health - Chao Family Comprehensive Cancer Center
- Sacramento, United States – University of California Davis Comprehensive Cancer Center
Age 18 and over
Contact the trial teamAn All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)
NCT07937124 · ClinicalTrials.gov
Age 18 and over
Contact the trial teamOlutasidenib for Relapsed IDH1-Mutated Acute Myeloid Leukemia After Venetoclax Treatment
NCT07471841 · ClinicalTrials.gov
Countries: United States
- Winston-Salem, United States – Atrium Health Wake Forest Baptist Medical Center
Age 18 and over
Contact the trial teamOlutasidenib After Donor Stem Cell Transplant in IDH1-Mutated Blood Cancers
NCT06543381 · ClinicalTrials.gov
Countries: United States
- Cleveland, United States – Cleveland Clinic Cancer Center
- Duarte, United States – City of Hope Medical Center
Age 18 and over
Contact the trial teamTests ivosidenib after stem cell transplant in leukemia with an IDH1 mutation
NCT06707493 · ClinicalTrials.gov
Countries: United States
- Atlanta, United States – Emory University Hospital
- Boston, United States – Dana-Farber Cancer Institute
- Boston, United States – Massachusetts General Hospital
Ages 18 to 75
Contact the trial teamIvosidenib and venetoclax, with or without azacitidine, for IDH1-mutated blood cancers
NCT03471260 · ClinicalTrials.gov
Countries: United States
- Boston, United States – Dana-Farber Cancer Institute
- Cleveland, United States – Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamTests enasidenib with azacitidine in acute myeloid leukemia with an IDH2 mutation
NCT03683433 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamTesting olutasidenib with other treatments in IDH1-mutant blood cancers
NCT07153497 · ClinicalTrials.gov
Age 18 and over
Contact the trial teamTests azacitidine with enasidenib in IDH2-mutant myelodysplastic syndrome
NCT03383575 · ClinicalTrials.gov
Countries: United States
- Baltimore, United States – Johns Hopkins University/Sidney Kimmel Cancer Center
- Cleveland, United States – Cleveland Clinic Foundation
- Houston, United States – M D Anderson Cancer Center
Age 12 and over
Contact the trial teamTests CPX-351 with ivosidenib in leukemia or high-risk MDS with IDH1 mutation
NCT04493164 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamTests how olutasidenib affects other drugs in people with IDH1-mutated cancers
NCT07486713 · ClinicalTrials.gov
Countries: United States
- New York, United States – New York Presbyterian Hospital-Columbia University Medical Center
- Orange, United States – UCI Irvine Health
Age 18 and over
Contact the trial teamCompares venetoclax with azacitidine to standard chemotherapy in newly diagnosed acute myeloid leukemia
NCT07664839 · ClinicalTrials.gov
Countries: China
- Shanghai, China – Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Ages 18 to 65
Contact the trial teamTests drug order in older adults with IDH-mutated acute myeloid leukemia
NCT05401097 · ClinicalTrials.gov
Countries: United States
- Aurora, United States – University of Colorado
- Chapel Hill, United States – UNC Hospitals, University of North Carolina at Chapel Hill
- Columbus, United States – Ohio State University Comprehensive Cancer Center
Age 18 and over
Contact the trial teamOlutasidenib for Acute Myeloid Leukemia With an IDH1 Mutation That Returned or Resisted Treatment
NCT07604064 · ClinicalTrials.gov
Age 18 and over
Contact the trial teamTests ivosidenib as ongoing treatment for leukemia and MDS with IDH1 mutation
NCT07607418 · ClinicalTrials.gov
Countries: China
- Shanghai, China – Ruijin hospital
Age 18 and over
Contact the trial teamVenetoclax, ivosidenib and azacitidine for newly diagnosed IDH1-mutated acute myeloid leukemia
NCT06611839 · ClinicalTrials.gov
Countries: China
- Tianjin, China – Blood Diseases Hospital
Age 14 and over
Contact the trial teamOlutasidenib, venetoclax and azacitidine for newly diagnosed IDH1-mutated acute myeloid leukemia
NCT06782542 · ClinicalTrials.gov
Countries: United States
- Miami, United States – University of Miami
Ages 18 to 75
Contact the trial teamTests HMPL-306 against chemotherapy in relapsed acute myeloid leukemia
NCT06387069 · ClinicalTrials.gov
Countries: China
- Baoding, China – Baoding NO.1 Central Hospital
- Beijing, China – Peking University People's Hospital
- Changchun, China – The First Hospital of Jilin University
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamIvosidenib with venetoclax and azacitidine for newly diagnosed IDH1-mutated acute myeloid leukemia
NCT07007949 · ClinicalTrials.gov
Countries: China
- Suzhou, China – The First Affiliated Hospital of Soochow University
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial team
How to get into an early trial
- A lab does not treat patients, so you cannot phone the lab to get a new treatment.
- Ask your doctor to look at phase 1 trials with you. These are the first tests in people.
- If one fits, your doctor sends a referral to the trial centre.
- The trial team checks whether you can join and decides.
Trial data: ClinicalTrials.gov, courtesy of the U.S. National Library of Medicine; it does not endorse this site. EU trials: EU Clinical Trials Information System (CTIS), European Medicines Agency. We show the registry records; the trial team has the last word on who can join.
Latest research
The five newest articles. The label comes from the PubMed index: whether it was tested in people, in animals or only in the lab.
- Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared to Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute Myeloid Leukemia With t(8;21) (q22;q22.1).J Hematol · 2026-10-31
- In animalsAll-Trans Retinoic Acid-Loaded Fe-N3-Se Single-Atom Nanozymes Enable Redox-Guided Differentiation Therapy for Acute Myeloid Leukemia.ACS Nano · 2026-11-17
- In animalsIntravital Microscopy-Guided Live-Cell Isolation for Spatially Resolved Transcriptional Analysis of Leukemia-Immune Interactions.J Vis Exp · 2026-11-10
- Impact of Molecular and Cytogenetic Risk Stratification, Early Treatment Response, and Inflammatory Biomarkers on Survival in Intensively Treated Non-Acute Promyelocytic Leukemia Acute Myeloid Leukemia.World J Oncol · 2026-11-11
- In peopleEarly bone marrow-guided venetoclax management in frontline unfit acute myeloid leukemia: a two-stage real-world study.Ann Hematol · 2026-08-20
Is it true?
Saw something on social media? Fact-check it now.
Get screened
For family members and people at higher risk: free checks can find some cancers early, before there are symptoms.
There is no routine screening for this cancer. If you have symptoms or a family history, talk to your doctor.
If several people in your family had cancer, ask your GP whether genetic counselling makes sense for you.
Offer tissue or data
You can help research move faster.
Give tissue or blood to research
Before an operation or a blood test, ask if left-over tissue or blood can go to a biobank.
- Does this hospital have a biobank?
- What will the sample be used for, and for how long?
- Can I change my mind later?
Share your health data
Ask your doctor whether there is a patient registry for your illness. You choose what you share.
Take part as a healthy volunteer
Some studies need people without the illness, often family members.
Volunteer studiesGet support
Patient groups in Austria
- Österreichische Krebshilfe
Free, anonymous counselling at regional centres in every federal state, psycho-oncology and emergency financial aid.
Phone: 01 7966450
Help for every illness in Austria (4)
- 1450 – Rund-um-die-Uhr-Gesundheitsberatung
Austria's nationwide 24/7 telephone health advice line: trained staff assess symptoms and guide callers to the appropriate care.
- Telefonseelsorge Österreich – Notruf 142
Free, confidential 24/7 emotional support and crisis line for anyone in Austria, reachable on 142.
- Gesundheitsportal Österreich (gesundheit.gv.at)
Austria's official public health portal, offering quality-assured information on diseases, prevention, health services and patient rights.
- ARGE Selbsthilfe Österreich
ARGE Selbsthilfe Österreich represents the interests of self-help groups and patient organisations in Austrian social and health policy.
Available abroad: international groups (8)
- DKMS
Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.
- Acute Leukemia Advocates Network (ALAN)
Global network of 69 acute leukaemia patient organisations (hosted by the Swiss Leukemia Patient Advocates Foundation); member list helps patients find a national group.
- European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
- European Reference Networks (European Commission)
The European Commission's 24 expert networks for rare and complex diseases; your doctor can contact them.
- EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
- Workgroup of European Cancer Patient Advocacy Networks
Network of pan-European cancer patient umbrella groups (including the blood cancer networks): joint advocacy, WECAN Academy training for patient advocates, patient experience data courses.
- European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
- International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Money and work
If the illness stops you working, ask the hospital social worker which benefits you can claim.
- Which sick-pay or disability benefits can I apply for?
- Is there help for the carer in the family?
- Are travel costs to treatment paid back?
After a loss
If someone you love has died, you do not have to go through it alone. Many families ask themselves whether they missed something; the care team can talk this through with you.
We have no grief support group in Austria in our list yet. The hospital's social worker or palliative team can tell you where to find one.
Hospitals and hospices have chaplains and counsellors, for any faith or none.
Some families decide to give tissue to research after death, so that the illness can be studied. If you want to, ask the treating hospital early whether it has such a programme.
Access and cost
- If no trial fits, your doctor can ask the company and the medicines authority whether early access (compassionate use) is possible.
- In Austria the medicines agency BASG lists the early-access programmes that are running. BASG (Austria): list of compassionate use programmes, no. 054
- In the EU you may get planned care in another EU country. Ask your health insurer before you go. Your Europe: planned medical treatment abroad
- Some medicines for this disease are approved abroad but maybe not here: see “Approved elsewhere” under “Approved in Austria” above.
Don't pay for this
No one will cure you through a Facebook message or ask you to invest money.
- Animal worm medicines bought online (ivermectin, fenbendazole)
They are made for animals and not tested for cancer in people. High doses can cause seizures or coma, fenbendazole has caused liver damage, they may weaken your cancer treatment, and they can keep you out of a trial.
American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025) · ASCO: Oncologists urged to discuss ivermectin and fenbendazole (17 Jun 2026)
- “Treatment plans” offered in comments
Ask which published study in people is behind it. Usually there is none.
- Anyone who answers your post with a private treatment
Real trials are listed in a public registry. Check the number on ClinicalTrials.gov or the EU trial register.
- Strangers offering investments or “funds” for treatment
Do not reply and do not send money. Report the comment or message.
Before you pay for anything, ask three things
- Can I have a written price, with everything that is included?
- Which published study in people shows it helps my disease?
- What does my doctor say about it?
Questions for your doctor
Ready lists for a new diagnosis, during treatment, before a trial and before you pay. Open the question lists
Not medical advice. We show what is open and what is known; your care team decides what fits you.